If there is still anyone monitoring this forum, I think I ought...

If there is still anyone monitoring this forum, I think I ought to post here at least one of the conclusions I reached evaluating the implications of the AOD9406-based "cellucreme" should it be taken to market by Phosphagenics.

I'm not going to repeat the entire post here. If anyone is interested, they can go to the POH forum and read the full analysis there.

But, here is the relevant conclusion for CZD:

"I would say that Calzada might expect an annual cash flow from royalties of between US$37,500,000 and US$112,500,000, or from 13 to 38 cents a share, supporting a share price of between US$2.50 and US$7.50 at a multiplier of 20."

For me, I'm hanging on to my old MBP, now CZD shares.